APA (7th ed.) Citation

A, S., C, K., CA, S., CF, N., C, M., HG, L., . . . B, K. (2016). Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer research, 76(21), 6331. https://doi.org/10.1158/0008-5472.CAN-16-0180

Chicago Style (17th ed.) Citation

A, Sommer, et al. "Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors." Cancer Research 76, no. 21 (2016): 6331. https://doi.org/10.1158/0008-5472.CAN-16-0180.

MLA (9th ed.) Citation

A, Sommer, et al. "Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors." Cancer Research, vol. 76, no. 21, 2016, p. 6331, https://doi.org/10.1158/0008-5472.CAN-16-0180.